PrecisionMed Inc. Launches Major Depressive Disorder (MDD) Cerebral Spinal Fluid Registry

<0> PrecisionMed Inc. Launches Major Depressive Disorder (MDD) Cerebral Spinal Fluid Registry </0>

PrecisionMed Inc.John Flax, MD, 858-847-0117 X 215

, the world’s leading supplier of human cerebral spinal fluid (CSF), today announced enrollment of the first four (4) donors into the PrecisionMed Major Depressive Disorder (MDD) Registry. The PrecisionMed MDD Registry is a biological sample bank of DNA and longitudinal CSF, RNA, serum and plasma linked to clinical data utilizing PrecisionMed’s clinical data procurement and clinical sample management capabilities.

The PrecisionMed MDD Registry will enroll up to 2000 donors. All donors will be recruited, evaluated, clinically studied, and sampled from up to 10 experienced investigative sites in the United States of America. Key aspects of donors’ clinical status will be evaluated every six months with simultaneous biological sampling.

“PrecisionMed develops cohorts of individuals for in-depth, longitudinal clinical and biological evaluation,” said John Flax, M.D., President and CEO of PrecisionMed. “In The MDD Registry, following establishment of baseline measures, the same validated measurements will be repeated every six months in order to quantify clinical changes, enabling correlation with biomarkers measured in corresponding samples. Accurate phenotyping is critical in relating changes in the clinical picture to alterations in molecular biomarkers. PrecisionMed has prior experience with longitudinal and single visit CSF banking projects in Alzheimer’s disease, mild cognitive impairment, schizophrenia, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, diabetic peripheral neuropathy and TruNormal® populations. These ongoing banked sample collections are an acknowledged, valuable source of highly annotated neuroscience samples, including CSF, to the research community worldwide.”

“Prospective study of a large sample of individuals using the MDD Registry design will enable pharmaceutical and academic researchers to study alterations in the clinical picture of MDD, using a multiplicity of biomarkers. By integrating the laboratory and clinical data, it should be possible to obtain important information for drug discovery, disease diagnosis, prediction of response to treatments and disease prognosis. The track record of PrecisionMed in this kind of collection is excellent and it bodes well that the clinical data and samples will be of the highest quality.”

Longitudinal samples with matched clinical data, collected from the same donors every six months, are available to our clients. Custom requests for additional sample types, as well as more complex clinical, laboratory and/or radiographic evaluations within selected subpopulations will be entertained as the registry matures.

PrecisionMed Inc., founded in 1994, is a privately held human biobank in the San Diego, California, area. PrecisionMed’s sample bank is a repository of human blood, DNA, RNA, PBMC, serum, plasma, urine and CSF linked to detailed de-identified audited clinical data. Samples are available to the pharmaceutical industry to enhance drug discovery and development, therapeutic target validation and molecular diagnostic product development. PrecisionMed provides customers access to samples with associated clinical information from a population of disease-specific donors and healthy matched controls. PrecisionMed is the world’s only supplier of CSF from TruNormal® donors. PrecisionMed is expanding its collections to include additional neuropsychiatric, neurodegenerative and other diseases. PrecisionMed offers custom sample collections in any disease area as well as custom CSF collections. PrecisionMed performs all of its sample collections in The United States of America.

Suggested Articles

Veterans Health Administration medical facilities currently have a paper medical record backlog that if stacked up would be 5.15 miles high, according to the…

The Department of Health and Human Services announced proposed changes to privacy restrictions on patients' substance use treatment records.

An FDA official said the agency is in discussions with multiple stakeholders to create a universal unique medical device identifier to be stored in EHRs.